Insilico Medicine’s AI Drug Rentosertib Reaches Phase III for IPF (2026)
What the Insilico Medicine AI Drug Rentosertib Does The Insilico Medicine AI drug rentosertib is moving into Phase III human trials, targeting idiopathic pulmonary fibrosis, a disease that scars lung tissue and
![File:InfografiaCRM.png: HakSOscar768 [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)]](https://welpmagazine.com/wp-content/uploads/2019/10/CRM_Software._Infografía.jpg)
